Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cimetidine + tiotropium is a combination of two pharmaceutical agents with distinct mechanisms of action and clinical indications. Cimetidine is a small molecule histamine H2 receptor antagonist that competitively inhibits histamine binding at the H2 receptor in gastric parietal cells, leading to reduced gastric acid secretion. It is primarily used for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, and related conditions[8]. Tiotropium is a long-acting antimuscarinic bronchodilator (anticholinergic) that acts as an antagonist at muscarinic acetylcholine receptors M1 to M5 in airway smooth muscle—most notably inhibiting the M3 receptor—to induce bronchodilation. Tiotropium is indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma[2][6]. There are no fixed-dose combination products containing both drugs; however, they may be co-administered in certain clinical scenarios. No clinically significant pharmacokinetic interaction has been observed between these agents[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cimetidine + tiotropium.